EXEL · Categories · Earnings
EXEL - Earnings announcements
Exelixis Inc. (EXEL) earnings announcements - real-time wire coverage filtered to Earnings only.
Recent Earnings for EXEL
- Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update- Total Revenues of $610.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $555.0 million - - GAAP Diluted EPS of $0.79, Non-GAAP Diluted EPS of $0.87 - - Announced Additional Stock Repurchase Program for up to $750 million by the End of 2027 - - Conference Call and Webcast Today at 5:00 PM ET - Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the first quarter of 2026, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones. "Exelixis made significant progress in the first quarter of 2026 as we remain focused on our goal of building next-generation oncology fr
- Exelixis to Release First Quarter 2026 Financial Results on Tuesday, May 5, 2026– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its first quarter 2026 financial results will be released on Tuesday, May 5, 2026 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the conference call, please register using this link. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.exelixis.com and proceed to the Event
- Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update– Total Revenues of $599 million for the Fourth Quarter of 2025, $2.320 billion for the Fiscal Year 2025 – – Cabozantinib Franchise Achieved $2.123 billion in U.S. Net Product Revenues for the Fiscal Year 2025, including $547 million for the Fourth Quarter of 2025 – – GAAP Diluted EPS of $0.88 for the Fourth Quarter of 2025, $2.78 for the Fiscal Year 2025 – – Conference Call and Webcast Today at 5:00 PM Eastern Time – Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the fourth quarter and fiscal year of 2025, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones. "Exelixis deli
- Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its fourth quarter and fiscal year 2025 financial results will be released on Tuesday, February 10, 2026 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the conference call, please register using this link. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.exelixis.com a
- Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update- Total Revenues of $597.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $542.9 million - - GAAP Diluted EPS of $0.69, Non-GAAP Diluted EPS of $0.78 - - Announced Additional Stock Repurchase Program for up to $750 million by the End of 2026 - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the third quarter of 2025, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones. "In the third quarter of 2025, Exelixis gained momentum in the cabozantinib franchise and delivered on critical strategic priorities
- Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its third quarter 2025 financial results will be released on Tuesday, November 4, 2025 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the conference call, please register using this link. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.exelixis.com and proceed to the
- Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update- Total Revenues of $568.3 million, Cabozantinib Franchise U.S. Net Product Revenues of $520.0 million - - GAAP Diluted EPS of $0.65, Non-GAAP Diluted EPS of $0.75 - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the second quarter of 2025, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones. "Exelixis continued to execute on our corporate objectives in the second quarter of 2025, delivering on key commercial, development and pipeline milestones," said Michael M. Morrissey, Ph.D., President and Chief Executiv
- Exelixis to Release Second Quarter 2025 Financial Results on Monday, July 28, 2025– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its second quarter 2025 financial results will be released on Monday, July 28, 2025 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the conference call, please register using this link. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.exelixis.com and proceed to the Eve
- Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update- Total Revenues of $555.4 million, Cabozantinib Franchise U.S. Net Product Revenues of $513.3 million - - GAAP Diluted EPS of $0.55, Non-GAAP Diluted EPS of $0.62 - - Increasing 2025 Full Year Net Product Revenues and Total Revenues Guidance by $100 million - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the first quarter of 2025, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones. "Exelixis delivered outstanding financial performance in the first quarter of 2025, driven by accelerating growth in CABOMETYX® d
- Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its first quarter 2025 financial results will be released on Tuesday, May 13, 2025 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the conference call, please register using this link. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.exelixis.com and proceed to the Event
- Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update- Total Revenues of $567 million for the Fourth Quarter of 2024, $2.17 billion for the Fiscal Year 2024 - - Cabozantinib Franchise Achieved $1.81 billion in U.S. Net Product Revenues for the Fiscal Year 2024, including $515 million for the Fourth Quarter of 2024 - - GAAP Diluted EPS of $0.48 for the Fourth Quarter of 2024, $1.76 for the Fiscal Year 2024 - - Non-GAAP Diluted EPS of $0.55 for the Fourth Quarter of 2024, $2.00 for the Fiscal Year 2024 - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the fourth quarter and fiscal year of 2024, provided an update on progress toward achieving key corporate objectiv
- Exelixis to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its fourth quarter and full year 2024 financial results will be released on Tuesday, February 11, 2025 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the conference call, please register using this link. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.exelixis.com and
- Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update- Total Revenues of $539.5 million, Cabozantinib Franchise U.S. Net Product Revenues of $478.1 million - - GAAP Diluted EPS of $0.40, Non-GAAP Diluted EPS of $0.47 - - Increasing Total Revenues and Net Product Revenues Guidance - - Favorable Ruling on Cabozantinib Patent Litigation Received from U.S. District Court - - Collaboration with Merck Expands Zanzalintinib Development Program - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the third quarter of 2024, provided an update on progress toward achieving key corporate objectives, and detailed its recent and anticipated commercial, clinical and pipeline
- Exelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its third quarter 2024 financial results will be released on Tuesday, October 29, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the conference call, please register using this link. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.exelixis.com and proceed to the Ev
- Exelixis Announces Second Quarter 2024 Financial Results and Provides Corporate Update- Total Revenues of $637.2 million, Cabozantinib Franchise U.S. Net Product Revenues of $437.6 million - - GAAP Diluted EPS of $0.77, Non-GAAP Diluted EPS of $0.84 - - U.S. Food and Drug Administration (FDA) Accepts Supplemental New Drug Application (sNDA) for Cabozantinib in Advanced Neuroendocrine Tumors (NET) - - Earned $150 million Cabozantinib Sales-Based Milestone from Ipsen - - Completed $450 million Stock Repurchase Program for 2024 - - Announced Additional Stock Repurchase Program for up to $500 million through the End of 2025 - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the second quarter of 20
- Exelixis to Release Second Quarter 2024 Financial Results on Tuesday, August 6, 2024– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its second quarter 2024 financial results will be released on Tuesday, August 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the conference call, please register using this link. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.exelixis.com and proceed to the E
- Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update- Total Revenues of $425 million, Cabozantinib Franchise U.S. Net Product Revenues of $379 million - - Restructuring Expenses of $32.8 million Recorded - - GAAP Diluted EPS of $0.12, Non-GAAP Diluted EPS of $0.17 - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the first quarter of 2024, provided an update on progress toward achieving key corporate objectives, and detailed its recent and anticipated commercial, clinical and pipeline development milestones. "In the first quarter of 2024, Exelixis made important progress to advance a diverse, multi-product portfolio of small molecules and biotherapeutic
- Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its first quarter 2024 financial results will be released on Tuesday, April 30, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the conference call, please register using this link. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.exelixis.com and proceed to the Ev
- Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update- Total Revenues of $480 million for the Fourth Quarter of 2023, $1,830 million for the Fiscal Year 2023 - - Cabozantinib Franchise Achieved $1,629 million in U.S. Net Product Revenues for the Fiscal Year 2023, including $429 million for the Fourth Quarter of 2023 - - GAAP Diluted EPS of $0.27 for the Fourth Quarter of 2023, $0.65 for the Fiscal Year 2023 - - Non-GAAP Diluted EPS of $0.33 for the Fourth Quarter of 2023, $0.90 for the Fiscal Year 2023 - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the fourth quarter and fiscal year of 2023, provided an update on progress toward achieving key corporat
- Exelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its fourth quarter and fiscal year 2023 financial results will be released on Tuesday, February 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the conference call, please register using this link. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.exelixis.com an
- Exelixis Announces Third Quarter 2023 Financial Results and Provides Corporate Update- Total Revenues of $471.9 million, Cabozantinib Franchise U.S. Net Product Revenues of $426.5 million - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the third quarter of 2023 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones. "The third quarter of 2023 was another strong one for the CABOMETYX® commercial franchise, which continues to fuel the buildout of our differentiated pipeline of small molecules and biotherapeutics," said Michael M. Morrissey, Ph.D., President and Chief Executive Officer, Exelixis. "CAB
- Exelixis to Release Third Quarter 2023 Financial Results on Wednesday, November 1, 2023– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its third quarter 2023 financial results will be released on Wednesday, November 1, 2023 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the conference call, please register using this link. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.exelixis.com and proceed to th
- Exelixis Announces Second Quarter 2023 Financial Results and Provides Corporate Update- Total Revenues of $469.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $409.6 million - - GAAP Diluted EPS of $0.25, Non-GAAP Diluted EPS of $0.31 - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the second quarter of 2023 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones. "In the second quarter of 2023, the Exelixis team continued to make steady progress both on our commercial business and our rapidly advancing pipeline," said Michael M. Morrissey, Ph.D., President and Chief Executive Office
- Exelixis to Release Second Quarter 2023 Financial Results on Tuesday, August 1, 2023– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its second quarter 2023 financial results will be released on Tuesday, August 1, 2023 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the conference call, please register using this link. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.exelixis.com and proceed to the N
- Exelixis Announces First Quarter 2023 Financial Results and Provides Corporate Update- Total Revenues of $408.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $363.4 million - - GAAP Diluted EPS of $0.12, Non-GAAP Diluted EPS of $0.16 - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the first quarter of 2023 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones. "The Exelixis team continued to execute on our key priorities and made significant progress in advancing our commercial business and our growing pipeline," said Michael M. Morrissey, Ph.D., President and Chief Executive Offi
- Exelixis to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its first quarter 2023 financial results will be released on Tuesday, May 9, 2023 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the conference call, please register using this link. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.exelixis.com and proceed to the News
- Exelixis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update- Total Revenues of $423.9 million for the Fourth Quarter of 2022, $1.61 billion for the Full Year 2022 - - Cabozantinib franchise achieved $1.40 billion in U.S. Net Product Revenues for the Full Year 2022, including $377.4 million for the Fourth Quarter 2022 - - GAAP Diluted EPS of $(0.09) for the Fourth Quarter of 2022, $0.56 for the Full Year 2022 - - Non-GAAP Diluted EPS of $(0.03) for the Fourth Quarter of 2022, $0.82 for the Full Year 2022 - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the fourth quarter and full year of 2022 and provided an update on progress toward achieving key corporate objecti
- Exelixis to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its fourth quarter and full year 2022 financial results will be released on Tuesday, February 7, 2023 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company's website at least 15 minutes prior to
- Exelixis Announces Third Quarter 2022 Financial Results and Provides Corporate Update– Total Revenues of $411.7 million, Cabozantinib Franchise Revenues of $366.5 million – – GAAP Diluted EPS of $0.23, Non-GAAP Diluted EPS of $0.31 – – Conference Call and Webcast Today at 5:00 PM Eastern Time – Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the third quarter of 2022 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones. "Exelixis focused its efforts toward the progress and expansion of our clinical and early-stage pipeline during the third quarter of 2022, fueled by the growing revenues from our cabozantinib franchise," said Michael M. Morrissey, Ph.D., President
- Exelixis to Release Third Quarter 2022 Financial Results on Tuesday, November 1, 2022– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its third quarter 2022 financial results will be released on Tuesday, November 1, 2022 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company's website at least 15 minutes prior to the conference
- Exelixis Announces Second Quarter 2022 Financial Results and Provides Corporate Update- Total Revenues of $419.4 million, Cabozantinib Franchise Revenues of $347.0 million - - GAAP Diluted EPS of $0.22, Non-GAAP Diluted EPS of $0.28 - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the second quarter of 2022 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones. "In the second quarter of 2022, Exelixis continued to execute across each of the core components of our business, highlighted in particular by our commercial and pipeline activities," said Michael M. Morrissey, Ph.D., President and Chief Executiv
- Exelixis to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its second quarter 2022 financial results will be released on Tuesday, August 9, 2022 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company's website at least 15 minutes prior to the conference c
- Exelixis Announces First Quarter 2022 Financial Results and Provides Corporate Update- Total Revenues of $356.0 million, Cabozantinib Franchise Revenues of $310.3 million - - GAAP Diluted EPS of $0.21, Non-GAAP Diluted EPS of $0.26 - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the first quarter of 2022 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones. "Exelixis had a strong start to 2022 as we continued to gain momentum across all components of our business," said Michael M. Morrissey, Ph.D., President and Chief Executive Officer, Exelixis. "We are pleased with the growth of the cabozantinib
- Exelixis to Release First Quarter 2022 Financial Results on Tuesday, May 10, 2022– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its first quarter 2022 financial results will be released on Tuesday, May 10, 2022 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company's website at least 15 minutes prior to the conference call
- Exelixis Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update- Total Revenues of $451.1 Million for the Fourth Quarter of 2021, $1.43 Billion for the Full Year 2021 - - Cabozantinib franchise achieved a significant milestone with $1.08 Billion in U.S. Net Product Revenues for the Full Year 2021, including $302.7 Million for the Fourth Quarter 2021 - - GAAP Diluted EPS of $0.29 for the Fourth Quarter of 2021, $0.72 for the Full Year 2021 - - Non-GAAP Diluted EPS of $0.35 for the Fourth Quarter of 2021, $1.01 for the Full Year 2021 - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the fourth quarter and full year 2021 and provided an update on progress toward achieving
- Exelixis to Release Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 17, 2022– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its fourth quarter and full year 2021 financial results will be released on Thursday, February 17, 2022 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company's website at least 15 minutes prior t
- Exelixis Announces Third Quarter 2021 Financial Results and Provides Corporate Update- Total Revenues of $328.4 Million, Cabozantinib Franchise Revenues of $263.1 Million - - GAAP Diluted EPS of $0.12, Non-GAAP Diluted EPS of $0.20 - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the third quarter of 2021 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones. "Exelixis continued to execute across all facets of our business in the third quarter of 2021 with significant progress across our commercial, clinical development and pipeline activities," said Michael M. Morrissey, Ph.D., President and Chief Exe
- Exelixis to Release Third Quarter 2021 Financial Results on Tuesday, November 2, 2021– Conference Call and Webcast to Follow at 5:00 p.m. EDT / 2:00 p.m. PDT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its third quarter 2021 financial results will be released on Tuesday, November 2, 2021 after the markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company's website at least 15 minutes prior to the confere
- Exelixis Announces Second Quarter 2021 Financial Results and Provides Corporate Update- Total Revenues of $385.2 Million, Cabozantinib Franchise Revenues of $284.2 Million - - GAAP Diluted EPS of $0.30, Non-GAAP Diluted EPS of $0.37 - - Raised Net Product Revenue Guidance to $1,050 - $1,150 Million and Total Revenue Guidance to $1,300 - $1,400 Million - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the second quarter of 2021 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones. "In the second quarter of 2021, Exelixis delivered a 59 percent year over year increase in CABOMETYX® net product revenue
- Exelixis to Release Second Quarter 2021 Financial Results on Thursday, August 5, 2021– Conference Call and Webcast to Follow at 5:00 p.m. EDT / 2:00 p.m. PDT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its second quarter 2021 financial results will be released on Thursday, August 5, 2021 after the markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company's website at least 15 minutes prior to the confere
- Exelixis In-Licenses Iconic Therapeutics’ Tissue Factor-Targeting Antibody-Drug Conjugate Ahead of Planned Investigational New Drug ApplicationALAMEDA, Calif., SOUTH SAN FRANCISCO, Calif. & VANCOUVER, British Columbia--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL), Iconic Therapeutics, Inc. (Iconic) and Zymeworks Inc. (NYSE:ZYME) today announced that Exelixis has exercised its exclusive option for Iconic’s lead oncology antibody-drug conjugate (ADC) program under the companies’ May 2019 agreement. As a result, Exelixis now has responsibility for the future clinical development, commercialization, and manufacturing of the Tissue Factor (TF)-targeting ADC now known as XB002 (formerly ICON-2). A rationally designed next-generation ADC, XB002 comprises a Tissue Factor-targeting antibody with Zymeworks’ proprietary ZymeLink™ l